APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaccine Particulate Adjuvants

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vaccine Particulate Adjuvants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025194 pages

Choose your research edition.

Industry ResearchVaccine Particulate Adjuvants Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine Particulate Adjuvants Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Vaccine Particulate Adjuvants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine Particulate Adjuvants Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine Particulate Adjuvants Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Vaccine Particulate Adjuvants market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Vaccine Particulate Adjuvants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vaccine Particulate Adjuvants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaccine Particulate Adjuvants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vaccine Particulate Adjuvants is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vaccine Particulate Adjuvants include Agenus, Inc(US), Avanti Polar Lipids, Inc(US), Brenntag Biosector (Denmark), CSL Limited (Australia), Invivogen (US), MVP Laboratories, Inc(US), Novavax, Inc(US), OZ Biosciences (France) and SEPPIC (France), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vaccine Particulate Adjuvants market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaccine Particulate Adjuvants and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaccine Particulate Adjuvants sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vaccine Particulate Adjuvants market size, projected growth trends, production technologies, key applications, and end-use industries.

Vaccine Particulate Adjuvants Segment by Company

Agenus, Inc(US)

Avanti Polar Lipids, Inc(US)

Brenntag Biosector (Denmark)

CSL Limited (Australia)

Invivogen (US)

MVP Laboratories, Inc(US)

Novavax, Inc(US)

OZ Biosciences (France)

SEPPIC (France)

SPI Pharma, Inc(US)

Vaccine Particulate Adjuvants Segment by Type

Subcutaneous

Intradermal

Oral

Intramuscular

Intranasal

Others

Vaccine Particulate Adjuvants Segment by Application

Infectious Diseases

Cancer

Others

Vaccine Particulate Adjuvants Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Particulate Adjuvants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine Particulate Adjuvants and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Particulate Adjuvants.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vaccine Particulate Adjuvants market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vaccine Particulate Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Vaccine Particulate Adjuvants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Vaccine Particulate Adjuvants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Vaccine Particulate Adjuvants Industry Trends Table 2. Vaccine Particulate Adjuvants Industry Drivers Table 3. Vaccine Particulate Adjuvants Industry Opportunities and Challenges Table 4. Vaccine Particulate Adjuvants Industry Restraints Table 5. Global Vaccine Particulate Adjuvants Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vaccine Particulate Adjuvants Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Vaccine Particulate Adjuvants Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Vaccine Particulate Adjuvants Sales Market Share by Manufacturers Table 9. Global Vaccine Particulate Adjuvants Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Vaccine Particulate Adjuvants Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vaccine Particulate Adjuvants Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vaccine Particulate Adjuvants Manufacturers, Product Type & Application Table 13. Global Vaccine Particulate Adjuvants Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vaccine Particulate Adjuvants by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Subcutaneous Table 17. Major Manufacturers of Intradermal Table 18. Major Manufacturers of Oral Table 19. Major Manufacturers of Intramuscular Table 20. Major Manufacturers of Intranasal Table 21. Major Manufacturers of Others Table 22. Global Vaccine Particulate Adjuvants Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Vaccine Particulate Adjuvants Sales by Type (2021-2026) & (W Units) Table 24. Global Vaccine Particulate Adjuvants Sales by Type (2027-2032) & (W Units) Table 25. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2026) Table 26. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2027-2032) Table 27. Global Vaccine Particulate Adjuvants Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 28. Global Vaccine Particulate Adjuvants Revenue by Type (2021-2026) & (W Units) Table 29. Global Vaccine Particulate Adjuvants Revenue by Type (2027-2032) & (W Units) Table 30. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2026) Table 31. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Infectious Diseases Table 33. Major Manufacturers of Cancer Table 34. Major Manufacturers of Others Table 35. Global Vaccine Particulate Adjuvants Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Vaccine Particulate Adjuvants Sales by Application (2021-2026) & (W Units) Table 37. Global Vaccine Particulate Adjuvants Sales by Application (2027-2032) & (W Units) Table 38. Global Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2026) Table 39. Global Vaccine Particulate Adjuvants Sales Market Share by Application (2027-2032) Table 40. Global Vaccine Particulate Adjuvants Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 41. Global Vaccine Particulate Adjuvants Revenue by Application (2021-2026) & (W Units) Table 42. Global Vaccine Particulate Adjuvants Revenue by Application (2027-2032) & (W Units) Table 43. Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2021-2026) Table 44. Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2027-2032) Table 45. Global Vaccine Particulate Adjuvants Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Vaccine Particulate Adjuvants Sales by Region (2021-2026) & (W Units) Table 47. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2021-2026) Table 48. Global Vaccine Particulate Adjuvants Sales Forecasted by Region (2027-2032) & (W Units) Table 49. Global Vaccine Particulate Adjuvants Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Vaccine Particulate Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 51. North America Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (W Units) Table 52. North America Vaccine Particulate Adjuvants Sales by Country (2027-2032) & (W Units) Table 53. Europe Vaccine Particulate Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Europe Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (W Units) Table 55. Europe Vaccine Particulate Adjuvants Sales by Country (2027-2032) & (W Units) Table 56. Asia Pacific Vaccine Particulate Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Asia Pacific Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (W Units) Table 58. Asia Pacific Vaccine Particulate Adjuvants Sales by Country (2027-2032) & (W Units) Table 59. South America, Middle East and Africa Vaccine Particulate Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. South America, Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2021-2026) & (W Units) Table 61. South America, Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2027-2032) & (W Units) Table 62. Global Vaccine Particulate Adjuvants Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Vaccine Particulate Adjuvants Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Vaccine Particulate Adjuvants Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2021-2026) Table 66. Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2027-2032) Table 67. Agenus, Inc(US) Company Information Table 68. Agenus, Inc(US) Business Overview Table 69. Agenus, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Agenus, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 71. Agenus, Inc(US) Recent Development Table 72. Avanti Polar Lipids, Inc(US) Company Information Table 73. Avanti Polar Lipids, Inc(US) Business Overview Table 74. Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 76. Avanti Polar Lipids, Inc(US) Recent Development Table 77. Brenntag Biosector (Denmark) Company Information Table 78. Brenntag Biosector (Denmark) Business Overview Table 79. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product Portfolio Table 81. Brenntag Biosector (Denmark) Recent Development Table 82. CSL Limited (Australia) Company Information Table 83. CSL Limited (Australia) Business Overview Table 84. CSL Limited (Australia) Vaccine Particulate Adjuvants Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. CSL Limited (Australia) Vaccine Particulate Adjuvants Product Portfolio Table 86. CSL Limited (Australia) Recent Development Table 87. Invivogen (US) Company Information Table 88. Invivogen (US) Business Overview Table 89. Invivogen (US) Vaccine Particulate Adjuvants Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Invivogen (US) Vaccine Particulate Adjuvants Product Portfolio Table 91. Invivogen (US) Recent Development Table 92. MVP Laboratories, Inc(US) Company Information Table 93. MVP Laboratories, Inc(US) Business Overview Table 94. MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 96. MVP Laboratories, Inc(US) Recent Development Table 97. Novavax, Inc(US) Company Information Table 98. Novavax, Inc(US) Business Overview Table 99. Novavax, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Novavax, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 101. Novavax, Inc(US) Recent Development Table 102. OZ Biosciences (France) Company Information Table 103. OZ Biosciences (France) Business Overview Table 104. OZ Biosciences (France) Vaccine Particulate Adjuvants Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. OZ Biosciences (France) Vaccine Particulate Adjuvants Product Portfolio Table 106. OZ Biosciences (France) Recent Development Table 107. SEPPIC (France) Company Information Table 108. SEPPIC (France) Business Overview Table 109. SEPPIC (France) Vaccine Particulate Adjuvants Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. SEPPIC (France) Vaccine Particulate Adjuvants Product Portfolio Table 111. SEPPIC (France) Recent Development Table 112. SPI Pharma, Inc(US) Company Information Table 113. SPI Pharma, Inc(US) Business Overview Table 114. SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Product Portfolio Table 116. SPI Pharma, Inc(US) Recent Development Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Vaccine Particulate Adjuvants Distributors List Table 120. Vaccine Particulate Adjuvants Customers List Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Vaccine Particulate Adjuvants Product Image Figure 2. Global Vaccine Particulate Adjuvants Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine Particulate Adjuvants Market Size (2021-2032) & (US$ Million) Figure 4. Global Vaccine Particulate Adjuvants Sales (2021-2032) & (W Units) Figure 5. Global Vaccine Particulate Adjuvants Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Vaccine Particulate Adjuvants Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Subcutaneous Image Figure 9. Intradermal Image Figure 10. Oral Image Figure 11. Intramuscular Image Figure 12. Intranasal Image Figure 13. Others Image Figure 14. Global Vaccine Particulate Adjuvants Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Vaccine Particulate Adjuvants Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2032) Figure 17. Global Vaccine Particulate Adjuvants Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Vaccine Particulate Adjuvants Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2032) Figure 20. Infectious Diseases Image Figure 21. Cancer Image Figure 22. Others Image Figure 23. Global Vaccine Particulate Adjuvants Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Vaccine Particulate Adjuvants Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2032) Figure 26. Global Vaccine Particulate Adjuvants Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Vaccine Particulate Adjuvants Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2021-2032) Figure 29. North America Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 30. North America Vaccine Particulate Adjuvants Sales Market Share by Country (2021-2032) Figure 31. U.S. Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Canada Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Mexico Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Vaccine Particulate Adjuvants Sales Market Share by Country (2021-2032) Figure 36. Germany Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 37. France Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 38. U.K. Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Italy Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Netherlands Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Vaccine Particulate Adjuvants Sales Market Share by Country (2021-2032) Figure 43. China Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Japan Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South Korea Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Southeast Asia Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 47. India Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Australia Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Vaccine Particulate Adjuvants Sales Market Share by Country (2021-2032) Figure 51. Brazil Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South Africa Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Saudi Arabia Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Turkey Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Argentina Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 56. UAE Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Egypt Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Chile Vaccine Particulate Adjuvants Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Global Vaccine Particulate Adjuvants Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Vaccine Particulate Adjuvants Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Figure 62. North America Vaccine Particulate Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Figure 64. Europe Vaccine Particulate Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Vaccine Particulate Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Vaccine Particulate Adjuvants Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Vaccine Particulate Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Vaccine Particulate Adjuvants Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Vaccine Particulate Adjuvants Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous
  • Intradermal
  • Oral
  • Intramuscular
  • Intranasal
  • Others
Applications
  • Infectious Diseases
  • Cancer
  • Others
Companies covered
  • Agenus, Inc(US)
  • Avanti Polar Lipids, Inc(US)
  • Brenntag Biosector (Denmark)
  • CSL Limited (Australia)
  • Invivogen (US)
  • MVP Laboratories, Inc(US)
  • Novavax, Inc(US)
  • OZ Biosciences (France)
  • SEPPIC (France)
  • SPI Pharma, Inc(US)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vaccine Particulate Adjuvants Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vaccine Particulate Adjuvants Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Vaccine Particulate Adjuvants Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Vaccine Particulate Adjuvants Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Vaccine Particulate Adjuvants Market Dynamics
  1. 2.1 Vaccine Particulate Adjuvants Industry Trends
  2. 2.2 Vaccine Particulate Adjuvants Industry Drivers
  3. 2.3 Vaccine Particulate Adjuvants Industry Opportunities and Challenges
  4. 2.4 Vaccine Particulate Adjuvants Industry Restraints
3 Vaccine Particulate Adjuvants Market by Manufacturers
  1. 3.1 Global Vaccine Particulate Adjuvants Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Vaccine Particulate Adjuvants Sales by Manufacturers (2021-2026)
  3. 3.3 Global Vaccine Particulate Adjuvants Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Vaccine Particulate Adjuvants Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vaccine Particulate Adjuvants Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vaccine Particulate Adjuvants Manufacturers, Product Type & Application
  7. 3.7 Global Vaccine Particulate Adjuvants Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vaccine Particulate Adjuvants Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vaccine Particulate Adjuvants Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vaccine Particulate Adjuvants Tier 1, Tier 2, and Tier 3
4 Vaccine Particulate Adjuvants Market by Type
  1. 4.1 Vaccine Particulate Adjuvants Type Introduction
  2. 4.1.1 Subcutaneous
  3. 4.1.2 Intradermal
  4. 4.1.3 Oral
  5. 4.1.4 Intramuscular
  6. 4.1.5 Intranasal
  7. 4.1.6 Others
  8. 4.2 Global Vaccine Particulate Adjuvants Sales by Type
  9. 4.2.1 Global Vaccine Particulate Adjuvants Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Vaccine Particulate Adjuvants Sales by Type (2021-2032)
  11. 4.2.3 Global Vaccine Particulate Adjuvants Sales Market Share by Type (2021-2032)
  12. 4.3 Global Vaccine Particulate Adjuvants Revenue by Type
  13. 4.3.1 Global Vaccine Particulate Adjuvants Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Vaccine Particulate Adjuvants Revenue by Type (2021-2032)
  15. 4.3.3 Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2021-2032)
5 Vaccine Particulate Adjuvants Market by Application
  1. 5.1 Vaccine Particulate Adjuvants Application Introduction
  2. 5.1.1 Infectious Diseases
  3. 5.1.2 Cancer
  4. 5.1.3 Others
  5. 5.2 Global Vaccine Particulate Adjuvants Sales by Application
  6. 5.2.1 Global Vaccine Particulate Adjuvants Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vaccine Particulate Adjuvants Sales by Application (2021-2032)
  8. 5.2.3 Global Vaccine Particulate Adjuvants Sales Market Share by Application (2021-2032)
  9. 5.3 Global Vaccine Particulate Adjuvants Revenue by Application
  10. 5.3.1 Global Vaccine Particulate Adjuvants Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Vaccine Particulate Adjuvants Revenue by Application (2021-2032)
  12. 5.3.3 Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2021-2032)
6 Global Vaccine Particulate Adjuvants Sales by Region
  1. 6.1 Global Vaccine Particulate Adjuvants Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaccine Particulate Adjuvants Sales by Region (2021-2032)
  3. 6.2.1 Global Vaccine Particulate Adjuvants Sales by Region (2021-2026)
  4. 6.2.2 Global Vaccine Particulate Adjuvants Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vaccine Particulate Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vaccine Particulate Adjuvants Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vaccine Particulate Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vaccine Particulate Adjuvants Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Vaccine Particulate Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Vaccine Particulate Adjuvants Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Vaccine Particulate Adjuvants Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Vaccine Particulate Adjuvants Revenue by Region
  1. 7.1 Global Vaccine Particulate Adjuvants Revenue by Region
  2. 7.1.1 Global Vaccine Particulate Adjuvants Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Vaccine Particulate Adjuvants Revenue by Region (2021-2026)
  4. 7.1.3 Global Vaccine Particulate Adjuvants Revenue by Region (2027-2032)
  5. 7.1.4 Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Vaccine Particulate Adjuvants Revenue (2021-2032)
  8. 7.2.2 North America Vaccine Particulate Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Vaccine Particulate Adjuvants Revenue (2021-2032)
  11. 7.3.2 Europe Vaccine Particulate Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Vaccine Particulate Adjuvants Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Vaccine Particulate Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Vaccine Particulate Adjuvants Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Vaccine Particulate Adjuvants Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Agenus, Inc(US)
  2. 8.1.1 Agenus, Inc(US) Company Information
  3. 8.1.2 Agenus, Inc(US) Business Overview
  4. 8.1.3 Agenus, Inc(US) Vaccine Particulate Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Agenus, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  6. 8.1.5 Agenus, Inc(US) Recent Developments
  7. 8.2 Avanti Polar Lipids, Inc(US)
  8. 8.2.1 Avanti Polar Lipids, Inc(US) Company Information
  9. 8.2.2 Avanti Polar Lipids, Inc(US) Business Overview
  10. 8.2.3 Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Avanti Polar Lipids, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  12. 8.2.5 Avanti Polar Lipids, Inc(US) Recent Developments
  13. 8.3 Brenntag Biosector (Denmark)
  14. 8.3.1 Brenntag Biosector (Denmark) Company Information
  15. 8.3.2 Brenntag Biosector (Denmark) Business Overview
  16. 8.3.3 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product Portfolio
  18. 8.3.5 Brenntag Biosector (Denmark) Recent Developments
  19. 8.4 CSL Limited (Australia)
  20. 8.4.1 CSL Limited (Australia) Company Information
  21. 8.4.2 CSL Limited (Australia) Business Overview
  22. 8.4.3 CSL Limited (Australia) Vaccine Particulate Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 CSL Limited (Australia) Vaccine Particulate Adjuvants Product Portfolio
  24. 8.4.5 CSL Limited (Australia) Recent Developments
  25. 8.5 Invivogen (US)
  26. 8.5.1 Invivogen (US) Company Information
  27. 8.5.2 Invivogen (US) Business Overview
  28. 8.5.3 Invivogen (US) Vaccine Particulate Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Invivogen (US) Vaccine Particulate Adjuvants Product Portfolio
  30. 8.5.5 Invivogen (US) Recent Developments
  31. 8.6 MVP Laboratories, Inc(US)
  32. 8.6.1 MVP Laboratories, Inc(US) Company Information
  33. 8.6.2 MVP Laboratories, Inc(US) Business Overview
  34. 8.6.3 MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 MVP Laboratories, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  36. 8.6.5 MVP Laboratories, Inc(US) Recent Developments
  37. 8.7 Novavax, Inc(US)
  38. 8.7.1 Novavax, Inc(US) Company Information
  39. 8.7.2 Novavax, Inc(US) Business Overview
  40. 8.7.3 Novavax, Inc(US) Vaccine Particulate Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novavax, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  42. 8.7.5 Novavax, Inc(US) Recent Developments
  43. 8.8 OZ Biosciences (France)
  44. 8.8.1 OZ Biosciences (France) Company Information
  45. 8.8.2 OZ Biosciences (France) Business Overview
  46. 8.8.3 OZ Biosciences (France) Vaccine Particulate Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 OZ Biosciences (France) Vaccine Particulate Adjuvants Product Portfolio
  48. 8.8.5 OZ Biosciences (France) Recent Developments
  49. 8.9 SEPPIC (France)
  50. 8.9.1 SEPPIC (France) Company Information
  51. 8.9.2 SEPPIC (France) Business Overview
  52. 8.9.3 SEPPIC (France) Vaccine Particulate Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 SEPPIC (France) Vaccine Particulate Adjuvants Product Portfolio
  54. 8.9.5 SEPPIC (France) Recent Developments
  55. 8.10 SPI Pharma, Inc(US)
  56. 8.10.1 SPI Pharma, Inc(US) Company Information
  57. 8.10.2 SPI Pharma, Inc(US) Business Overview
  58. 8.10.3 SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 SPI Pharma, Inc(US) Vaccine Particulate Adjuvants Product Portfolio
  60. 8.10.5 SPI Pharma, Inc(US) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vaccine Particulate Adjuvants Value Chain Analysis
  2. 9.1.1 Vaccine Particulate Adjuvants Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vaccine Particulate Adjuvants Production Mode & Process
  6. 9.2 Vaccine Particulate Adjuvants Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vaccine Particulate Adjuvants Distributors
  9. 9.2.3 Vaccine Particulate Adjuvants Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst